Tyers Asset Management LLC Has $697,000 Position in Hologic (HOLX)

Tyers Asset Management LLC increased its position in shares of Hologic (NASDAQ:HOLX) by 19.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,648 shares of the medical equipment provider’s stock after acquiring an additional 3,080 shares during the period. Tyers Asset Management LLC’s holdings in Hologic were worth $697,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Hologic during the 1st quarter worth approximately $146,000. Synovus Financial Corp bought a new stake in Hologic during the 1st quarter worth approximately $164,000. NuWave Investment Management LLC bought a new stake in Hologic during the 4th quarter worth approximately $199,000. Fiduciary Trust Co. bought a new stake in Hologic during the 4th quarter worth approximately $208,000. Finally, Advisor Partners LLC bought a new stake in Hologic during the 4th quarter worth approximately $209,000. 98.47% of the stock is currently owned by institutional investors and hedge funds.

Shares of Hologic opened at $38.82 on Friday, MarketBeat.com reports. The firm has a market capitalization of $10.60 billion, a PE ratio of 19.12, a P/E/G ratio of 1.83 and a beta of 0.87. Hologic has a one year low of $35.10 and a one year high of $46.80. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.98 and a current ratio of 1.26.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $789.30 million for the quarter, compared to analyst estimates of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.50 EPS. research analysts expect that Hologic will post 2.24 EPS for the current fiscal year.

In other news, VP Karleen Marie Oberton sold 12,196 shares of the stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the transaction, the vice president now owns 13,825 shares of the company’s stock, valued at approximately $553,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Charles J. Dockendorff bought 13,000 shares of Hologic stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average cost of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. 0.79% of the stock is owned by corporate insiders.

HOLX has been the topic of a number of analyst reports. BidaskClub lowered shares of Hologic from a “sell” rating to a “strong sell” rating in a report on Thursday, January 25th. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 target price on shares of Hologic in a report on Friday, February 9th. Deutsche Bank decreased their target price on shares of Hologic from $44.00 to $42.00 and set a “hold” rating on the stock in a report on Thursday, May 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $48.00 target price on shares of Hologic in a report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $44.87.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply